EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

ALCAT1 promotes diabetic cardiomyopathy by linking myocardial tetralinoleoyl cardiolipin deficiency to lipotoxicity

Dandan Jia, Yuguang Shi

Molecular Therapy · 2026

DOI: 10.1016/j.ymthe.2026.01.025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026. Verfasst von Dandan Jia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Barshop Institute for Longevity and Aging Studies, Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio,…. Hauptthemen laut MEDLINE: Cardiolipins, Diabetic Cardiomyopathies, Myocardium, Acyltransferases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NIDDK NIH HHS, American Diabetes Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiolipin (CL) is a mitochondria-specific phospholipid essential for maintaining cardiac bioenergetic function. In diabetes, the depletion of tetralinoleoyl cardiolipin (TLCL), the predominant CL species in healthy myocardium, has been implicated in the pathogenesis of diabetic cardiomyopathy (DCM). However, the mechanisms underlying TLCL loss remain poorly understood. ALCAT1, an acyltransferase that mediates pathological remodeling of CL under oxidative stress, has been proposed as a key factor in this process. Using a cardiac-specific ALCAT1 knockout mouse model, we demonstrate a causal role of ALCAT1 in the onset and progression of DCM. We show that hyperglycemia-induced upregulation of ALCAT1 leads to TLCL depletion, mitochondrial dysfunction, and lipotoxicity in the heart. Remarkably, cardiac ablation of ALCAT1 not only restored TLCL content and mitochondrial function but it also mitigated DCM by promoting fatty acid oxidation in the heart. These findings identify ALCAT1 as a central mediator of diabetic cardiomyopathy through its disruption of fatty acid oxidation and mitochondrial integrity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiolipinsDiabetic CardiomyopathiesMyocardiumAcyltransferasesAnimalsMiceMice, KnockoutOxidative StressDisease Models, AnimalMitochondria, HeartFatty AcidsMitochondriaOxidation-Reduction

Stichwörter der Autor:innen

diabetic cardiomyopathyinflammationmitochondrial dysfunctionoxidative stress

Substanzen

CardiolipinstetralinoleoylcardiolipinAcyltransferasesFatty Acids

Autor:innen und Institutionen

  • Barshop Institute for Longevity and Aging Studies, Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
  • Barshop Institute for Longevity and Aging Studies, Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. Electronic address: shiy4@uthscsa.edu.

Förderung

  • NIA NIH HHS
  • NIDDK NIH HHS
  • American Diabetes Association
  • Barth Syndrome Foundation
  • National Institutes of Health

Zitieren

APA

Jia, D., & Shi, Y. (2026). ALCAT1 promotes diabetic cardiomyopathy by linking myocardial tetralinoleoyl cardiolipin deficiency to lipotoxicity. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.01.025

Vancouver

Jia D, Shi Y. ALCAT1 promotes diabetic cardiomyopathy by linking myocardial tetralinoleoyl cardiolipin deficiency to lipotoxicity. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.01.025

BibTeX
@article{Jia2026,
  author = {Jia, Dandan and Shi, Yuguang},
  title = {ALCAT1 promotes diabetic cardiomyopathy by linking myocardial tetralinoleoyl cardiolipin deficiency to lipotoxicity},
  journal = {Molecular Therapy},
  year = {2026},
  doi = {10.1016/j.ymthe.2026.01.025}
}
Kostenlos starten →